Biktarvy - Another INSTI-Based Combination for HIV
Biktarvy - Another INSTI-Based Combination for HIV
August 13, 2018 (Issue: 1553)
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide...more
- Emtricitabine/tenofovir alafenamide (Descovy) for HIV. Med Lett Drugs Ther 2016; 58:100.
- Genvoya – a new 4-drug combination for HIV. Med Lett Drugs Ther 2016; 58:19.
- Odefsey – another NNRTI combination for HIV. Med Lett Drugs Ther 2016; 58:60.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV-1. US Department of Health and Human Services. Available at: aidsinfo.nih.gov. Accessed July 16, 2018.
- J Gallant et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 2017; 390:2063.
- PE Sax et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet 2017; 390:2073.
- J-M Molina et al. Switch to bictegravir/F/TAF from DTG and ABC/3TC. Presented at Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, March 4-7, 2018. Abstract 22. Available at: www.croiconference.org. Accessed July 16, 2018.
- E Daar et al. Phase 3 randomized, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: week 48 results. Presented at ID Week, San Diego, CA, October 4-8, 2017. Abstract LB-4. Available at: www.idsa.confex.com. Accessed July 16, 2018.
- C Kityo et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women. Presented at Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, March 4-7, 2018. Abstract 500. Available at: www.croiconference. org. Accessed July 16, 2018.
- Drugs for HIV infection. Treat Guidel Med Lett 2014; 12:7.
- PE Sax et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606.
- M Tsiang et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 2016; 60:7086.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed July 16, 2018.
- K Rough et al. Birth outcomes for pregnant women with HIV using tenofovir-emtricitabine. N Engl J Med 2018; 378:1593.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Biktarvy - Another INSTI-Based Combination for HIV
Article code: 1553b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
